12:00 AM
 | 
Sep 20, 2010
 |  BC Week In Review  |  Company News  |  Other News

Avanir, The Michael J. Fox Foundation for Parkinson's Research neurology news

Avanir received a grant of about $570,000 from the foundation to study AVP-923 to treat Parkinson's disease (PD) levodopa-induced dyskinesia (PD-LID). Next year, Avanir will start a double-blind, placebo-controlled, North American Phase II trial to evaluate AVP-923 in...

Read the full 172 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >